These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 11354394

  • 1. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
    Simmons ST, Alphagan/Trusopt Study Group.
    Clin Ther; 2001 Apr; 23(4):604-19. PubMed ID: 11354394
    [Abstract] [Full Text] [Related]

  • 2. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.
    Simmons ST, Samuelson TW.
    Clin Ther; 2000 Apr; 22(4):388-99. PubMed ID: 10823361
    [Abstract] [Full Text] [Related]

  • 3. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST, Earl ML, Alphagan/Xalatan Study Group.
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC, Sharpe ED, Day DG, Kolker AE, Konstas AG, Lee WH, Rieser JC, Chopra H, Holmes KT.
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [Abstract] [Full Text] [Related]

  • 5. [Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers].
    Carrasco Font C, Arias Puente A, García Sáenz MC, Villarejo Díaz-Maroto I.
    Arch Soc Esp Oftalmol; 2004 Apr; 79(4):163-8. PubMed ID: 15124072
    [Abstract] [Full Text] [Related]

  • 6. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE, Lai J.
    Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A, Paczka JA, Jiménez-Román J, Hartleben C.
    BMC Ophthalmol; 2014 Dec 19; 14():161. PubMed ID: 25527295
    [Abstract] [Full Text] [Related]

  • 8. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
    Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S, Hollander DA.
    Curr Med Res Opin; 2009 Jul 19; 25(7):1645-53. PubMed ID: 19476406
    [Abstract] [Full Text] [Related]

  • 9. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
    Hommer A, Kapik B, Shams N, Unoprostone Adjunctive Therapy Study Group.
    Br J Ophthalmol; 2003 May 19; 87(5):592-8. PubMed ID: 12714402
    [Abstract] [Full Text] [Related]

  • 10. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma.
    Centofanti M, Manni G, Gregori D, Cocco F, Lorenzano D, Bucci MG.
    Graefes Arch Clin Exp Ophthalmol; 2000 Apr 19; 238(4):302-5. PubMed ID: 10853928
    [Abstract] [Full Text] [Related]

  • 11. Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
    Nguyen QH, Earl M.
    J Ocul Pharmacol Ther; 2009 Dec 19; 25(6):541-4. PubMed ID: 20028261
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
    Whitson JT, Henry C, Hughes B, Lee DA, Terry S, Fechtner RD.
    J Glaucoma; 2004 Apr 19; 13(2):168-73. PubMed ID: 15097265
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
    Katz LJ, Simmons ST, Craven ER.
    Curr Med Res Opin; 2007 Dec 19; 23(12):2971-83. PubMed ID: 17949534
    [Abstract] [Full Text] [Related]

  • 14. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures.
    Solish AM, DeLucca PT, Cassel DA, Kolodny AH, Hustad CM, Skobieranda F.
    J Glaucoma; 2004 Apr 19; 13(2):149-57. PubMed ID: 15097262
    [Abstract] [Full Text] [Related]

  • 15. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
    DuBiner HB, Mroz M, Shapiro AM, Dirks MS, Brimonidine vs. Latanoprost Study Group.
    Clin Ther; 2001 Dec 19; 23(12):1969-83. PubMed ID: 11813932
    [Abstract] [Full Text] [Related]

  • 16. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension.
    Sharpe ED, Day DG, Beischel CJ, Rhodes JS, Stewart JA, Stewart WC.
    Br J Ophthalmol; 2004 Jul 19; 88(7):953-6. PubMed ID: 15205246
    [Abstract] [Full Text] [Related]

  • 17. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R, Queiroz CF, Santos LC, Avila MP, Magacho L.
    Clin Ther; 2006 Apr 19; 28(4):552-9. PubMed ID: 16750466
    [Abstract] [Full Text] [Related]

  • 18. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
    Sall KN, Greff LJ, Johnson-Pratt LR, DeLucca PT, Polis AB, Kolodny AH, Fletcher CA, Cassel DA, Boyle DR, Skobieranda F.
    Ophthalmology; 2003 Mar 19; 110(3):615-24. PubMed ID: 12623832
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group.
    Boyle JE, Ghosh K, Gieser DK, Adamsons IA.
    Ophthalmology; 1998 Oct 19; 105(10):1945-51. PubMed ID: 9787368
    [Abstract] [Full Text] [Related]

  • 20. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
    Boyle JE, Ghosh K, Gieser DK, Adamsons IA.
    Ophthalmology; 1999 Dec 19; 106(12 Suppl):10-6. PubMed ID: 10598692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.